Cell-based therapy for idiopathic pulmonary fibrosis

Abstract

state imbalance in pulmonary epithelial cells (2,3). Currently, there is no effective treatment for this endstage lung fibrosis disease. However, some FDA-approved therapeutic agents, including pirfenidone and nintedanib, can clearly reduce the average decrease in the function of the lung in the IPF patients (3,4).Current studies have investigated whether the pathogenesis of IPF is related to chronic epithelial injury that leads to abnormalities of the wound healing process, and both fibroblast proliferation and activation, rather than

Induced pluripotent stem cell-derived lung alveolar epithelial type II cells reduce damage in bleomycin-induced lung fibrosis

“…Over the last decade, a great number of preclinical studies based in cell therapies have been conducted as prospective treatment for IPF. Various types of cells have been used, including different stem cells such as bone marrow-derived mesenchymal cells, hematopoietic stem cells, adipose stem cells, embryonic stem cells, iPSC, and lung stem cells [13,28,29]. Additionally, AEC2 and lung mixed epithelial cells have also been investigated [13,28,29].…”

“…Various types of cells have been used, including different stem cells such as bone marrow-derived mesenchymal cells, hematopoietic stem cells, adipose stem cells, embryonic stem cells, iPSC, and lung stem cells [13,28,29]. Additionally, AEC2 and lung mixed epithelial cells have also been investigated [13,28,29]. Usually, most cell replacement therapy strategies have been assayed as a pretreatment, after 24 h of BLM administration or during the early stages of fibrosis development 3 or 7 days after BLM [13,28,29].…”

“…Additionally, AEC2 and lung mixed epithelial cells have also been investigated [13,28,29]. Usually, most cell replacement therapy strategies have been assayed as a pretreatment, after 24 h of BLM administration or during the early stages of fibrosis development 3 or 7 days after BLM [13,28,29]. In general, cell administration during these initial stages of the disease showed very promising results, because many of these cell types are able to inhibit the inflammatory response, leading to the slowdown of fibrogenesis.…”

“…Cell transplantation therapy to treat lung disease has been proposed before; the most widely tested cell types are bone marrow mesenchymal stromal cells [13], but also other cell types such as cord blood mesenchymal stem cells, human amnion epithelial cells (hAEC) [14], and AEC2 in both animal and human clinical studies [15][16][17]. AEC2 are responsible for repairing the damaged alveolar epithelium in the event of lung damage and consequently proposed as an optimal cell type for the treatment of IPF.…”

A Flowable Placental Formulation Prevents Bleomycin-Induced Dermal Fibrosis in Aged Mice

“…The beneficial effects of the aforementioned anti-fibrotic therapies have been studied and proven in several organs, including the lungs [ 11 , 15 ], heart [ 16 ], kidney [ 17 ], liver [ 18 ], abdominal injury [ 14 ] and skin [ 11 , 19 ]. Therefore, the anti-inflammatory and anti-fibrotic properties of human placenta and umbilical tissue make both well-suited as therapeutic agents to prevent inflammation and fibrosis [ 14 , 20 , 21 , 22 , 23 ].…”